> CAT ABOUT :: PUBLISHER // READ-ONLY EVIDENCE TERMINAL
About TB-500 Script — an independent editorial record.
What this project is, what "script" means here, and the firm line between summarizing a literature and prescribing from it.
What TB-500 Script is
TB-500 Script is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built as a read-only evidence terminal. Each finding is logged with the species it was measured in, the dose and route, and a status flag — LOGGED for what the published research establishes, PRECLINICAL for animal-and-in-vitro signals, and NULL for the records that are absent. We chose that format because the TB-500 record demands it: more than almost any compound, this one is a story of missing and unreliable data, and a surface that renders absence honestly is a more faithful vehicle than a confident dashboard.
What "script" means here
The word "script" in this site's name is editorial framing, not a service. It does not mean we write prescriptions, fill them, or facilitate them — we do none of those things, and nothing here is dispensed or sold. We read "script" the way a system reads a log: a record of what the literature says, who studied it, where the human data run out, and how compounded access actually stands under FDA rules.
That distinction is the whole point of the publisher's position. We occupy a stance relative to the literature — we transcribe and index it — not a stance relative to any patient. The regulatory page states the present-tense FDA facts and the lawful compounding pathway in general terms; it is not, and cannot be, medical or legal advice, and it is not an offer to supply anything.
How we handle the evidence
Two rules govern every page. First: every quantitative claim cites a study, and the citation names the species and the molecule. We do not let a rat re-epithelialization figure imply a human outcome, and we do not let a full-length thymosin beta-4 result stand in for the TB-500 fragment without flagging it. Second: we describe what was administered to which species at which dose by which route — never what a person should take. There are no human dosing recommendations on this site, because the record does not contain a validated human protocol for the fragment.
Where the record is strong, we say so plainly. Where it reads NULL — no completed human trial of the heptapeptide, no validated human half-life, a tumor-biology caution that no human study has resolved — we leave that visible rather than soften it. That is the editorial standard this project holds itself to.